Evidence map›Paper›PMID 21757725›Full record

ArticleThe Journal of biological chemistry2011

L-Ala-γ-D-Glu-meso-diaminopimelic acid (DAP) interacts directly with leucine-rich region domain of nucleotide-binding oligomerization domain 1, increasing phosphorylation activity of receptor-interacting serine/threonine-protein kinase 2 and its interaction with nucleotide-binding oligomerization domain 1.

Hamed Laroui, Yutao Yan, Yoshie Narui, Sarah A Ingersoll, Saravanan Ayyadurai, Moiz A Charania, Feimeng Zhou, Binghe Wang, Khalid Salaita, Shanthi V Sitaraman and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Synthesis of aMolecules (Basel, Switzerland) · 2024
    Article
  6. Review
  7. NOD1: a metabolic modulator.Frontiers in endocrinology · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Revisiting peptidoglycan sensing: interactions with host immunity and beyond.Chemical communications (Cambridge, England) · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hamed LarouiDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322. Electronic address: hlaroui@emory.edu.
Yutao YanDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322.
Yoshie NaruiDepartment of Chemistry, Emory University, Atlanta, Georgia 30322.
Sarah A IngersollDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322.
Saravanan AyyaduraiDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322.
Moiz A CharaniaDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322.
Feimeng ZhouDepartment of Chemistry and Biochemistry, California State University, Los Angeles, California 90032.
Binghe WangDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30302-4098.
Khalid SalaitaDepartment of Chemistry, Emory University, Atlanta, Georgia 30322.
Shanthi V SitaramanDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322.
Didier MerlinDepartment of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia 30322; Veterans Affairs Medical Center, Decatur, Georgia 30033.
Emory University · USCalifornia State University Los Angeles · USGeorgia State University · US

Funding

NOVEL DRUG DESIGN AND HIGH THROUGHPUT SCREENINGP20MD001824 · NIMHD · CALIFORNIA STATE UNIVERSITY LOS ANGELES · PI VELLANOWETH, ROBERT · 2005 to 2009
$4.4M
ROLE OF CD98 IN INTESTINAL PERMEABILITYR01DK071594 · NIDDK · GEORGIA STATE UNIVERSITY · PI MERLIN, DIDIER · 2006 to 2017
$3.3M
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATIONR01DK055850 · NIDDK · EMORY UNIVERSITY · PI ZIEGLER, THOMAS R · 2000 to 2004
$1.5M
Intestinal PepT1 in Health and DiseaseR56DK084987 · NIDDK · GEORGIA STATE UNIVERSITY · PI MERLIN, DIDIER · 2010 to 2010
$367k
NCI NIH HHS SC1MS070155-01NIDDK NIH HHS R01 DK055850NIDDK NIH HHS R01 DK071594NIDDK NIH HHS R01-DK-071594NIDDK NIH HHS R01-DK-55850NIDDK NIH HHS R56 DK084987NIMHD NIH HHS P20 MD001824NIMHD NIH HHS P20-MD001824-01
6 · The paper itself

Abstract

The oligopeptide transporter PepT1 expressed in inflamed colonic epithelial cells transports small bacterial peptides, such as muramyl dipeptide (MDP) and l-Ala-γ-D-Glu-meso-diaminopimelic acid (Tri-DAP) into cells. The innate immune system uses various proteins to sense pathogen-associated molecular patterns. Nucleotide-binding oligomerization domain (NOD)-like receptors of which there are more than 20 related family members are present in the cytosol and recognize intracellular ligands. NOD proteins mediate NF-κB activation via receptor-interacting serine/threonine-protein kinase 2 (RICK or RIPK). The specific ligands for some NOD-like receptors have been identified. NOD type 1 (NOD1) is activated by peptides that contain a diaminophilic acid, such as the PepT1 substrate Tri-DAP. In other words, PepT1 transport activity plays an important role in controlling intracellular loading of ligands for NOD1 in turn determining the activation level of downstream inflammatory pathways. However, no direct interaction between Tri-DAP and NOD1 has been identified. In the present work, surface plasmon resonance and atomic force microscopy experiments showed direct binding between NOD1 and Tri-DAP with a K(d) value of 34.5 μM. In contrast, no significant binding was evident between muramyl dipeptide and NOD1. Furthermore, leucine-rich region (LRR)-truncated NOD1 did not interact with Tri-DAP, indicating that Tri-DAP interacts with the LRR domain of NOD1. Next, we examined binding between RICK and NOD1 proteins and found that such binding was significant with a K(d) value of 4.13 μM. However, NOD1/RICK binding was of higher affinity (K(d) of 3.26 μM) when NOD1 was prebound to Tri-DAP. Furthermore, RICK phosphorylation activity was increased when NOD was prebound to Tri-DAP. In conclusion, we have shown that Tri-DAP interacts directly with the LRR domain of NOD1 and consequently increases RICK/NOD1 association and RICK phosphorylation activity.

Indexed as

BiophysicsCaco-2 CellsDiaminopimelic AcidHumansImmunity, InnateInflammationLeucineMicroscopy, Atomic ForceNod1 Signaling Adaptor ProteinNucleotidesOligopeptidesPeptidesPhosphorylationProtein BindingProtein Structure, TertiaryReverse Transcriptase Polymerase Chain ReactionDiaminopimelic AcidL-Ala-gamma-D-Glu-meso-diaminopimelic acidLeucineNod1 Signaling Adaptor ProteinNucleotidesOligopeptidesPeptidesRNA, Small Interfering

Identifiers

PMID21757725
PMCPMC3162459
OpenAlexW2085955533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.